FDA approves extended-release oxycodone with abuse-deterrent properties

July 24, 2014 6:35 AM

11 0

FDA approves extended-release oxycodone with abuse-deterrent properties

MILWAUKEE (WITI) — The U.S. Food and Drug Administration approved Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), an extended-release/long-acting (ER/LA) opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Targiniq ER is the second ER/LA opioid analgesic with FDA-approved labeling describing the product’s abuse-deterrent properties consistent with the FDA’s 2013 draft guidance for industry, Abuse-Deterrent Opioids – Evaluation and Labeling.

Read more

To category page

Loading...